ERBB2 and neoplasm: This approach has been employed in studies targeting tumor cells via tumor-associated antigens such as HER2 [48], EGFR [10], and EpCAM [49] or immune cells through immunological receptors like CD20 [15], CD19 [50], CD8 [51], CD4 [52], and CD30 [23].